Can a biomarker predict who responds to a new AML combo?
NCT ID NCT02583893
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested whether certain biomarkers in bone marrow can predict how well patients with high-risk acute myeloid leukemia (AML) respond to treatment with sirolimus plus standard chemotherapy (MEC). The study enrolled 39 adults with AML that was hard to treat or had come back. Researchers measured changes in a protein called pS6 in bone marrow samples to see if it could forecast remission. The goal was to find a way to personalize treatment for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sirolimus (Rapamycin) combined with chemotherapy (Mitoxantrone, Etoposide, Cytarabine)
- What this could lead to
- If successful, this could help doctors predict which high-risk AML patients will respond to sirolimus plus chemotherapy, leading to more personalized treatment.
- What could go wrong
- This is a small, early-phase study (39 patients) focused on biomarkers, not a direct test of a new cure. The results may not apply to all AML patients, and the chemotherapy has significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ADULT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Can a Platelet-Boosting drug speed recovery for older leukemia patients?
- Radioactive antibody hones in on cancer cells to boost transplant success
- Precision radiation may boost stem cell transplant success in tough leukemias
- Could a targeted drug keep AML in check?